Overall, however, these findings nonetheless suggest that both MAPK pathway inhibition (e.g. via MEK inhibitors) and p53 pathway inhibition (e.g. via MDM2 inhibitors) are important therapeutic axes for development in canine melanoma just as they are in human [38]. This evidence concerns the gene TP53 and melanoma.